ATP4B
Potassium-transporting ATPase subunit beta
As of the edition of 20 October 2026, ATP4B (potassium-transporting ATPase subunit beta, UniProt P51164) has 7 drugs tested at it and 10 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P51164
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Digestive system; Bones, joints and muscles; Cancer; Heart and blood vessels; Infections; Blood and lymph; Immune system; Chemically induced
- Registered trials of its drugs
- 237
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 3 |
| Went quiet | 3 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vonoprazan | Marketed | Phase 4 | Ends 2032 |
| Tegoprazan | Active | Phase 4 | none listed |
| Abeprazan | Active | Phase 4 | none listed |
| Ilaprazole | Active | Phase 4 | none listed |
| PN 400 | Went quiet | Phase 1 | none listed |
| D961H | Went quiet | Phase 3 | none listed |
| Revaprazan | Went quiet | Phase 2 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 8 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Pozen | Route A |
The other 8 companies at ATP4B
In the product10 companies in all; 8 are not named here, and no score is.
See the 10 companies at ATP4B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.